Combination therapy for chronic hepatitis B

Journal of Hepatology

Volumn 39, Issue SUPPL. 1, 2003, Pages

  Schalm, Solko W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; CREATININE; ENTECAVIR; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 12; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; VIRUS DNA;

ANTIVIRAL ACTIVITY; BLEEDING; CHRONIC HEPATITIS; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG EFFICACY; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 0141637197     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(03)00352-0     Document Type: Conference Paper

References (11)

1. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-568.
2. Barbaro G, Zechini F, Pellicelli AM, Francavilla R, Scotto G, Bacca D, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter randomized trial. J Hepatol 2001;35:406-411.
3. Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perillo RP, Husa P, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:818-826.
4. Sanantonio T, Niro GA, Sinisi E, Leandro G, Insalata M, Pastore G, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B: a controlled pilot study. J Hepatol 2002;36:799-804.
5. Tatulli I, Francavilla R, Rizzo GL, Vinciguerra V, Ierardi E, Francavilla A, et al. Lamivudine and alpha-interferon in combination for precore mutant chronic hepatitis B. J Hepatol 2001;35:805-810.
6. Benhamou Y, Bochet M, Thibault V, Calvez V, Katlama C, Poynard T, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-723.
7. Perrillo R, Schiff E, Hann HWL, Buti M, Strasse S, Watkins KM, et al. The addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis B with YMDD variant HBV and reduced response to lamivudine. Hepatology 2001;34 Suppl:349A.
8. Schiff ER, Neuhaus P, Tillmann H, Samuel D, Terrault N, Marcellin P, et al. Safety and efficacy of adefovir dipivoxil for the treatment of lamivudine resistant HBV in patients post liver transplantation. Hepatology 2001;34 Suppl:446A.
9. Serfaty L, Thabut D, Zoulim F, Andrean T, Chazouillères O, Carbonell N, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001;34:573-577.
10. Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 2002;66:452-460.
11. Peters M, Hann HW, Martin P, Heathcote E, Buggisch P, Moorat AE, et al. Adefovir dipivoxll (ADV) alone and in combination with lamivudine (LAM) suppresses lam-resistant hepatitis B virus (HBV) replication: 16 week interim analysis. J Hepatol 2002;36 Suppl:6-7.